Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCE: Once-daily eliglustat in stable CYP2D6 intermediate and extensive metabolizers with Gaucher disease type 1
NL-OMON61759Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eliglustat in Gaucher disease type 1 (GD1), sponsored by Amsterdam University Medical Center. Primary endpoint: Clinical stability at Month 12. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NL-OMON61759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61759.